Oct. 23 at 3:40 AM
$BBIO Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating
5
Save
Comments
Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating
Oct. 22, 2025 11:20 PM ETAurinia Pharmaceuticals Inc. (AUPH) StockAUPH

Gamu Dave Innocent Pasi
110 Followers
5
Share
Save
Play(11min)
Comments
Summary
Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development.
AUPH's Lupkynis leads as the first FDA-approved oral therapy for lupus nephritis, with 22% YoY revenue growth and expanding physician adoption.
The company's pipeline drug, AUR200, targets dual immune proteins and offers long-term diversification potential in a multi-billion-dollar autoimmune market.
Key risks include heavy reliance on Lupkynis, patent expirations, and competitive pressures, but current financial strength supports ongoing R&D and expansion.

Moment Makers Group/iStock via Getty Images
